| Expression pattern: |
UP |
| Associated gene: |
SCD1 mRNA, ELAVL1 |
| Associated microRNA: |
- |
| Biological function: |
Suppresses ferroptosis and promotes gastric cancer cell proliferation, migration/metastasis, and tumor progression. |
| Molecular mechanism: |
Direct binding to SCD1 mRNA and recruitment of ELAVL1 to stabilize SCD1 mRNA and enhance translation, promoting lipid metabolic reprogramming and ferroptosis resistance. |
| Biological pathway or process: |
ferroptosis (inhibits); metastasis (promotes); proliferation (promotes); migration (promotes); lipid metabolism (promotes); mRNA stability (promotes); other pathway/process (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; Bioinformatics Analysis; RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; Clinical Sample Validation; ROC Analysis; Transfection; CCK8; Colony Formation Assay; Transwell Assay; RIP (RNA Immunoprecipitation); RNA Pull-Down; Western Blot; IHC (Immunohistochemistry); ELISA; In Vivo Animal Model; Flow Cytometry（Non-apoptosis/cycle） |
| Clinical significance: |
Plasma circTFRC levels were associated with tumor size and distant metastatic status and showed diagnostic value by ROC analysis (AUC 0.865 for GC vs healthy controls; AUC 0.737 for distant metastasis vs no distant metastasis). |
| Description: |
circTFRC is upregulated in gastric cancer tissues, cell lines, and patient plasma, and its higher plasma level correlates with tumor size and distant metastasis. Functionally, circTFRC promotes GC proliferation and metastasis and suppresses ferroptosis by directly binding SCD1 mRNA and recruiting ELAVL1 to increase SCD1 mRNA stability/translation, supporting lipid metabolic reprogramming. |
| Confidence score: |
0.8837 |